AL-SHADOWDRAGON
14.4.2024 18:01:30 CEST | Business Wire | Press release
ShadowDragon™, a provider of ethical open-source intelligence (OSINT) software, unique datasets and APIs, is pleased to announce significant enhancements to its flagship Open-Source Intelligence Investigative platform Horizon®. These updates represent a milestone in the evolution of investigative technology, offering capabilities to streamline investigative processes and uncover valuable insights.
The OSINT Platform encompasses an all-in-one solution for investigations with unparalleled access to publicly available information, including geolocation data, platform monitoring, breach data and the ability to integrate external data streams. This allows for a modern approach to link analysis in one comprehensive toolkit. Horizon® offers access to more than 225 data collection sources, more than 1500 pivot points, and advanced, customizable link analysis capabilities.
Horizon® is accessible with any internet connection and allows users to access critical data and conduct investigations from any device, providing unprecedented flexibility and mobility. Mapping advancements, plotting capability, visual geofencing, and geoestimation allow for different starting points that pinpoint precise locations and uncover valuable insights. Horizon® offers unmatched ease of integration, creating tailored data streams able to solve for any problem set. Horizon® will also enable analysts the ability to work on the go from a tablet, phone, or desktop/laptop.
Horizon®, coupled with ShadowDragon’s SocialNet ® offers a powerful OSINT toolkit that includes more than 225 data collection sources to use for correlating publicly available data, integrated brand monitoring, breach data inquiries, social media information and link analysis capabilities to empower users with a holistic approach to investigations. Users benefit from advanced link analysis capabilities, allowing them to connect the dots and uncover actionable intelligence with ease.
CEO Daniel Clemens said, “Our customers have asked for a unified platform for many years. We are answering their requests with Horizon®, enabling customers to use our platform and data with their existing tools, easily import and export data, while enabling greater focus for complex analysis of data. The Horizon® Platform allows publicly available data to tell the story for the analyst. I am very delighted at what our team has produced and thankful to how our tools help protect many on a global scale.”
“You guys are doing incredible things with SocialNet® and Horizon®. Looking back as a user of Horizon's early release, it has been the coolest privilege to experience the last three years of innovation, watching the platform evolve and morph with every incremental update, and knowing there are always more tweaks still in the works.” - Law Enforcement Customer.
These updates underscore ShadowDragon's commitment to innovation and excellence in the field of investigative technology. By continuously enhancing its OSINT suite with new features, data collection sources and capabilities, ShadowDragon aims to empower investigators with the tools they need to stay ahead of emerging threats and make informed decisions.
Nico Dekens, ShadowDragon Director of Intelligence, said, "This is as close as one can get to having a silver bullet solution that helps solve investigative and analytical needs. This means that no matter what OSINT expertise you have, ShadowDragon's technology will speed up your investigation through an initiative platform. But it is not limited to just the platform and tools, the seasoned team will train you on usage and will support you in getting the most out of your investigative needs. The newly released features and capabilities will make your work future proof and will speed up ANY investigation significantly."
For more information about the ShadowDragon™ suite of OSINT tools and capabilities, such as SocialNet®, OIMonitor®, MalNet®, and Horizon®, click here.
About ShadowDragon
ShadowDragon™ provides comprehensive, cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open source intelligence (OSINT) from over 225 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for Good”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240413210644/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release
Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release
Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
